Daré Bioscience, Inc.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US23666P1012

USD

2.75

-0.16 (-5.5%)

May 08

NAS

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Fortress Biotech, Inc.

Assembly Biosciences, Inc.

Sol-Gel Technologies Ltd.

Daré Bioscience, Inc.

Societal CDMO, Inc.

SELLAS Life Sciences Group, Inc.

Rezolute, Inc.

Minerva Neurosciences, Inc.

MEI Pharma, Inc.

Kineta, Inc.

SciSparc Ltd.

Why is Daré Bioscience, Inc. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Flat results in Sep 25

RAW MATERIAL COST(Y) Grown by 35,793.38% (YoY)

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -46.37%, its profits have fallen by -134.4%

Falling Participation by Institutional Investors

Institutional investors have decreased their stake by -9.35% over the previous quarter and collectively hold 8.52% of the company
These investors have better capability and resources to analyse fundamentals of companies than most retail investors

Below par performance in long term as well as near term

Along with generating -46.37% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Daré Bioscience, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Daré Bioscience, Inc.

-5.82%

-1.30

56.41%

S&P 500

30.63%

0.62

19.30%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.98%

EBIT Growth (5y)

1.98%

EBIT to Interest (avg)

-26.98

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.33

Sales to Capital Employed (avg)

-0.11

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.52%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.35

EV to EBIT

-0.34

EV to EBITDA

-0.37

EV to Capital Employed

-0.45

EV to Sales

5.64

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-582.07%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-1What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 35,793.38% (YoY

Here's what is not working for Daré Bioscience, Inc.

Raw Material Cost

Grown by 35,793.38% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales